Compound details
Estra-1,3,5(10),16-tetraen-3-ol benzoate
| Compound ID | CDAMM00152 |
|---|---|
| Common name | Estra-1,3,5(10),16-tetraen-3-ol benzoate | IUPAC name | [(8S,9S,13R,14S)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-yl] benzoate |
| Molecular formula | C25H26O2 |
| Retention time | 43.68 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 359.2 | Theoretical mz | 359.201 |
| Error | 2.64 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 4.5128 |
| Inchi key | KHAIFVOAJPIDQL-AHCIIZGASA-N |
|---|---|
| Smiles | CC12CCC3C(C1CC=C2)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5 |
| Superclass | Lipids and lipid-like molecules |
| Class | Steroids and steroid derivatives |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P42330 | AKR1C3 | Aldo-keto-reductase family 1 member C3 | T60857 | SEA |
| Q92731 | ESR2 | Estrogen receptor beta | T80896 | SEA |
| P08185 | SERPINA6 | Corticosteroid binding globulin | T88452 | SEA |
| P11511 | CYP19A1 | Cytochrome P450 19A1 | T13260 | SEA |
| Q07869 | PPARA | Peroxisome proliferator-activated receptor alpha | T86591 | SEA |
| Q03181 | PPARD | Peroxisome proliferator-activated receptor delta | T36557 | SEA |
| P03372 | ESR1 | Estrogen receptor alpha | T02506 | SEA |
| P33527 | ABCC1 | Multidrug resistance-associated protein 1 | T11288 | SEA |
| O95718 | ESRRB | Estrogen-related receptor beta | T42025 | SEA |
| P08842 | STS | Steryl-sulfatase | T33489 | SEA |
| Q14330 | GPR18 | N-arachidonyl glycine receptor | T72267 | SEA |
| Q9Y6L6 | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | T46814 | SEA |
| Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | T65236 | SEA |
| P10323 | ACR | Acrosin | T24595 | SEA |
| O75751 | EMTH | Organic cation transporter 3 | T55948 | SEA |
| O15439 | ABCC4 | Multidrug resistance protein 4 | T39919 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T60857 | DI0145 | Female pelvic pain | [ICD-11: GA34] | P42330 | AKR1C3 |
| T80896 | DI0062 | Breast cancer | [ICD-11: 2C60-2C6Y] | Q92731 | ESR2 |
| T80896 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | Q92731 | ESR2 |
| T80896 | DI0254 | Menopausal disorder | [ICD-11: GA30] | Q92731 | ESR2 |
| T80896 | DI0432 | Vasomotor/allergic rhinitis | [ICD-11: CA08] | Q92731 | ESR2 |
| T88452 | DI0037 | Asthma | [ICD-11: CA23] | P08185 | SERPINA6 |
| T88452 | DI0339 | Postoperative inflammation | [ICD-11: 1A00-CA43] | P08185 | SERPINA6 |
| T88452 | DI0362 | Respiratory system disease | [ICD-11: CB40-CB7Z] | P08185 | SERPINA6 |
| T13260 | DI0062 | Breast cancer | [ICD-11: 2C60-2C6Y] | P11511 | CYP19A1 |
| T13260 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | P11511 | CYP19A1 |
| T86591 | DI0187 | Hyperlipidemia | [ICD-11: 5C80] | Q07869 | PPARA |
| T86591 | DI0188 | Hyper-lipoproteinaemia | [ICD-11: 5C80] | Q07869 | PPARA |
| T86591 | DI0417 | Type 2 diabetes mellitus | [ICD-11: 5A11] | Q07869 | PPARA |
| T36557 | DI0302 | Non-alcoholic fatty liver disease | [ICD-11: DB92] | Q03181 | PPARD |
| T36557 | DI0308 | Obesity | [ICD-11: 5B80-5B81] | Q03181 | PPARD |
| T02506 | DI0106 | COVID-19 | [ICD-11: 1D6Y] | P03372 | ESR1 |
| T11288 | DI0167 | Gout | [ICD-11: FA25] | P33527 | ABCC1 |
| T33489 | DI0022 | Allergic/hypersensitivity disorder | [ICD-11: 4A80-4A8Z] | P08842 | STS |
| T65236 | DI0100 | Contraceptive management | [ICD-11: QA21] | Q99527 | GPER1 |